Search Results
Search results for "Nobel Prize"
Results found for "Nobel Prize"
- GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for...
We synthesized and characterized a novel A2AAR antagonist, 2 (LJ-4517), with Ki = 18.3 nM.
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
announced that its collaboration agreement with Indivior PLC (LON: INDV) for discovering and developing novel
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
Oliver Hartley, Orion’s Vice-President Drug Discovery, will present Orion’s novel technology for targeting
- Helix 8 in chemotactic receptors of the complement system
Orthosteric and allosteric antagonists of C5aR1 are a novel strategy for anti-inflammatory therapies.
- 📰 GPCR Weekly News, March 6 to 12, 2023
Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
GPCR University 🎥 Recorded GPCR Courses and Symposia / Summit 💲 Special Pricing on GPCR courses prognosis in nasopharyngeal carcinoma RNAi library screening reveals Gβ1, Casein Kinase 2 and ICAP-1 as novel
- Coincident Regulation of PLCβ Signaling by Gq-Coupled and μOpioid Receptors Opposes Opioid- Mediated
Gβγ regulation of PLCβ3, enhances the potency of the antinociceptive effects of morphine suggesting a novel
- A broad look into the future of systemic sclerosis
Extracellular vesicles are another novel player to possess disease processes.
- 📰 GPCR Weekly News, April 10 to 16, 2023
GPCR Binders, Drugs, and more Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
intelligence (AI), machine learning, and the design of protein structures in the discovery and development of novel
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
undoubtedly continue to propel our quest to unravel the complexities of GPCR signaling and pave the way for novel Jiang, L.I., et al., Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine
- 📰 GPCR Weekly News, December 18 to 31, 2023
Endocrinology, and Taste Beta cell primary cilia mediate somatostatin responsiveness via SSTR3 Inhibition of a novel Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel
- Comparative study of neuropeptide signaling systems in Hemiptera
research provides more knowledge on neuropeptide systems and sets the groundwork for the creation of novel
- VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron
receptors) in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel
- California gold rush for Sosei Heptares
The vision is to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric
- Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system, emerging...
receptor activation, make this receptor an intriguing target for treating schizophrenia, a disease where novel
- 📰 GPCR Weekly News, February 27 to March 5, 2023
Developing novel antifungals: lessons from G protein-coupled receptors. Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Don’t miss this chance to benefit from our early bird pricing and premium content. Russell to Board of Directors Adiso Announces Groundbreaking Research Highlighting ADS024 a Novel Oral
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
debutante Septerna swells its IPO to $331m Nxera Pharma and Antiverse Enter Collaboration To Design Novel signalling: Yet another variant route in a highly complex road map Transactivation of the EGF receptor as a novel
- Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
striking deficit of both NPS receptor (NPSR1) and NPS precursor knockout mice in fear extinction or novel
- A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
Recent studies introducing setmelanotide, a novel synthetic MC4R agonist, suggest a predominant role
- GPR84 signaling promotes intestinal mucosal inflammation via enhancing NLRP3 inflammasome activation
CLH536, a novel GPR84 antagonist discovered by us, suppresses colitis by reducing the polarization and
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
compounds that have been evaluated as rhodopsin modulators to be considered as leads for the development of novel
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
to generalize this accuracy to synthetic compounds, limiting its utility in drug discovery involving novel
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
revealed the location of allosteric binding sites and opened new opportunities for the discovery of novel
- 📰 GPCR Weekly News, February 20 to 26, 2023
Structural and Molecular Insights into GPCR Function Structure-based design of novel melanin-concentrating Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
revealed the location of allosteric binding sites and opened new opportunities for the discovery of novel



